TARA
Protara Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.15 / 10
Netural
Analyst coverage is limited to one source (Piper Sandler) with a unanimous Buy rating and a 100% historical win rate, contributing positively to sentiment. Money flow is robust (7.53/10) with overall inflow ratio of 0.4307, though individual blocks (Small, Medium, Large, Extra-large) show negative trends. The combination of strong conviction from a single analyst and positive fund momentum offsets some fundamental weaknesses but not enough to elevate the overall rating beyond neutral.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-07
InstitutionPiper Sandler
Times predicted1
Historical Win Rate100.0%
Is money flowing into or out of TARA?
- TARA holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.15/10 (Netural).
